A Conduct of the inquiry

Outlined in this appendix are details relating to consultations through:

* submissions received (table A.1)
* initial visits (table A.2).

The Commission received the terms of reference for this inquiry on 29 June 2012. Following receipt of the terms of reference, the Commission placed notices in the press and on its website inviting public participation in the inquiry. Information about the inquiry was also circulated to people and organisations likely to have an interest in it.

The Commission released an issues paper in August 2012 to assist inquiry participants with preparing their submissions. The Commission received 35 submissions.

The Commission is grateful to all those who have contributed to this inquiry and now seeks additional input. It welcomes further submissions in response to this draft report. The Commission also invites participation in public hearings to be held in mid-February 2013. More information about the consultation processes is provided at the front of this report.

Table A.1 Submissionsa

|  |  |
| --- | --- |
| Participant | Submission number |
| Advisory Council on Intellectual Property | 35 |
| Alliance for Clean Technology Innovation | 9 |
| Alphapharm | 30 |
| Association of Australian Medical Research Institutes | 17 |
| Ausbiotech | 21 |
| Australian Fair Trade and Investment Network | 23 |
| Biotechnology Industry Organisation | 27 |
| Bouvier, Scott | 2# |
| Business SA | 20 |
| Centre for Law and Genetics | 3 |
| Civil Liberties Australia | 12 |
| Commonwealth Scientific and Industrial Research Organisation | 26 |
| Croplife | 6 |
| CSL | 5 |
| Department of Health and Ageing (Australian Government) | 22 |
| Dwyer Lawyers | 1 |
| FB Rice | 7 |
| Federal Court of Australia | 29 |
| Generic Medicines Industry Association | 34 |
| GM Holden Ltd | 19 |
| Institute of Patent and Trade Mark Attorneys | 18 |
| Janssen Cilag Pty Ltd | 28 |
| Law Council of Australia | 32 |
| Medicines Australia | 10 |
| Moir, Dr Hazel | 31# |
| National Coalition of Public Pathology | 25 |
| National Health and Medical Research Council | 33 |
| Peter MacCallum Cancer Centre | 14 |
| Pfizer Australia | 24 |
| Public Health Association of Australia | 4 |
| Rimmer, Dr Matthew | 11, 15 |
| Royal College of Pathologists of Australasia | 16# |
| Telstra Corporation Limited | 8 |
| The Walter and Eliza Hall Institute of Medical Research | 13 |
|  |  |
|  |  |

a # indicates that the submission includes attachments.

Table A.2 Visits

|  |
| --- |
| Participant and location |
| **Canberra** |
| CropLife Australia |
| Department of Health and Ageing (Australian Government) |
| Department of Industry, Innovation, Science, Research and Tertiary Education  (Australian Government) |
| Department of Foreign Affairs and Trade (Australian Government) |
| Ergas, Henry |
| IP Australia |
| Medicines Australia |
| The Treasury (Australian Government) |
|  |
| **Melbourne** |
| Australian Competition and Consumer Commission (Australian Government) |
| Advisory Council on Intellectual Property |
| Commonwealth Science and Industrial Research Organisation (CSIRO) |
| Davies Collison Cave |
| Heath, Ian |
| Institute of Patent and Trademark Attorneys |
| Intellectual Property Research Institute of Australia |
| Law Council of Australia |
| Licensing Executives Society of Australia and New Zealand |
| Melbourne Business School |
| Melbourne Law School |
| Middleton, Justice John |
| Walter and Eliza Hall Institute of Medical Research |
|  |
| **Sydney** |
| Australian Law Reform Commission |
| Cancer Voices Australia |
| CSIRO |
| Westmead Hospital |
|  |